Limits...
Radiofrequency ablation of unresectable colorectal liver metastases: trends in management and outcome during a decade at a single center.

Labori KJ, Schulz A, Drolsum A, Guren MG, Kløw NE, Bjørnbeth BA - Acta Radiol Open (2015)

Bottom Line: At least one risk factor for recurrence was found in patients with local recurrence (n = 11): subcapsular localization (n = 4), tumor size >3 cm and subcapsular localization (n = 2), and perivascular localization (portal veins/hepatic veins) (n = 5).Over time, the morbidity and survival have improved in RFA of CRLM.Although a possible effect of a learning curve should be taken into consideration in the appraisal of this improvement, it is more likely to be attributable to optimization of indication, development in surgical techniques, and increased use of perioperative chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.

ABSTRACT

Background: Radiofrequency ablation (RFA) is widely used for treatment of colorectal liver metastases (CRLM).

Purpose: To evaluate the effect of increased experience in RFA of CRLM on morbidity and survival, and the trends in patient management and outcomes during the last decade.

Material and methods: Hospital records of the initial 52 consecutive patients who underwent RFA (56 procedures/70 lesions) were retrospectively reviewed. The patients were divided into two groups according to time period of treatment, period I (2001-2006: n = 26) and period II (2007-2011: n = 26).

Results: Concomitant liver resection was performed in 15 patients in each period. Operative morbidity decreased from 47% to 19% (P = 0.047). Most complications were found in patients who underwent a concomitant liver resection and not related to the ablation per se. Local recurrence rate decreased from 19.4% to 12.9% (P = 0.526). At least one risk factor for recurrence was found in patients with local recurrence (n = 11): subcapsular localization (n = 4), tumor size >3 cm and subcapsular localization (n = 2), and perivascular localization (portal veins/hepatic veins) (n = 5). Median overall survival was 32 months in period I and 49 months in period II, whereas estimated 5-year survival was 19% and 36%, respectively (P = 0.09). Adjuvant chemotherapy was given to four patients (15.4%) in period I and 13 patients (50%) in period II (P = 0.017).

Conclusion: RFA alone or in combination with liver resection is a potentially curative treatment to selected patients with CRLM. Over time, the morbidity and survival have improved in RFA of CRLM. Although a possible effect of a learning curve should be taken into consideration in the appraisal of this improvement, it is more likely to be attributable to optimization of indication, development in surgical techniques, and increased use of perioperative chemotherapy.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier analysis of disease-free survival in 50 consecutive patients treated with RFA of unresectable CRLM stratified into period I (2001–2006) and period II (2007–2011).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2 - License 3
getmorefigures.php?uid=PMC4548748&req=5

fig1-2058460115580877: Kaplan-Meier analysis of disease-free survival in 50 consecutive patients treated with RFA of unresectable CRLM stratified into period I (2001–2006) and period II (2007–2011).

Mentions: Median disease-free survival (DFS), overall survival (OS), and 5-year OS rates for the whole period were 11 months (95% CI, 4.3–17.8), 36 months (95% CI, 27.3–44.7), and 27%, respectively. Median DFS was 10 months (95 % CI, 5.2–14.7) in period I and 11 months (95% CI, 0.2–21.8) in period II (P = 0.098) (Fig. 1). Median OS was 32.0 months (95% CI, 25.8–38.2) in period I and 49.0 months (95% CI, 28.4–69.6) in period II, whereas estimated 5-year OS was 19% in period I and 36% in period II (P = 0.09) (Fig. 2).Fig. 1.


Radiofrequency ablation of unresectable colorectal liver metastases: trends in management and outcome during a decade at a single center.

Labori KJ, Schulz A, Drolsum A, Guren MG, Kløw NE, Bjørnbeth BA - Acta Radiol Open (2015)

Kaplan-Meier analysis of disease-free survival in 50 consecutive patients treated with RFA of unresectable CRLM stratified into period I (2001–2006) and period II (2007–2011).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License 1 - License 2 - License 3
Show All Figures
getmorefigures.php?uid=PMC4548748&req=5

fig1-2058460115580877: Kaplan-Meier analysis of disease-free survival in 50 consecutive patients treated with RFA of unresectable CRLM stratified into period I (2001–2006) and period II (2007–2011).
Mentions: Median disease-free survival (DFS), overall survival (OS), and 5-year OS rates for the whole period were 11 months (95% CI, 4.3–17.8), 36 months (95% CI, 27.3–44.7), and 27%, respectively. Median DFS was 10 months (95 % CI, 5.2–14.7) in period I and 11 months (95% CI, 0.2–21.8) in period II (P = 0.098) (Fig. 1). Median OS was 32.0 months (95% CI, 25.8–38.2) in period I and 49.0 months (95% CI, 28.4–69.6) in period II, whereas estimated 5-year OS was 19% in period I and 36% in period II (P = 0.09) (Fig. 2).Fig. 1.

Bottom Line: At least one risk factor for recurrence was found in patients with local recurrence (n = 11): subcapsular localization (n = 4), tumor size >3 cm and subcapsular localization (n = 2), and perivascular localization (portal veins/hepatic veins) (n = 5).Over time, the morbidity and survival have improved in RFA of CRLM.Although a possible effect of a learning curve should be taken into consideration in the appraisal of this improvement, it is more likely to be attributable to optimization of indication, development in surgical techniques, and increased use of perioperative chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.

ABSTRACT

Background: Radiofrequency ablation (RFA) is widely used for treatment of colorectal liver metastases (CRLM).

Purpose: To evaluate the effect of increased experience in RFA of CRLM on morbidity and survival, and the trends in patient management and outcomes during the last decade.

Material and methods: Hospital records of the initial 52 consecutive patients who underwent RFA (56 procedures/70 lesions) were retrospectively reviewed. The patients were divided into two groups according to time period of treatment, period I (2001-2006: n = 26) and period II (2007-2011: n = 26).

Results: Concomitant liver resection was performed in 15 patients in each period. Operative morbidity decreased from 47% to 19% (P = 0.047). Most complications were found in patients who underwent a concomitant liver resection and not related to the ablation per se. Local recurrence rate decreased from 19.4% to 12.9% (P = 0.526). At least one risk factor for recurrence was found in patients with local recurrence (n = 11): subcapsular localization (n = 4), tumor size >3 cm and subcapsular localization (n = 2), and perivascular localization (portal veins/hepatic veins) (n = 5). Median overall survival was 32 months in period I and 49 months in period II, whereas estimated 5-year survival was 19% and 36%, respectively (P = 0.09). Adjuvant chemotherapy was given to four patients (15.4%) in period I and 13 patients (50%) in period II (P = 0.017).

Conclusion: RFA alone or in combination with liver resection is a potentially curative treatment to selected patients with CRLM. Over time, the morbidity and survival have improved in RFA of CRLM. Although a possible effect of a learning curve should be taken into consideration in the appraisal of this improvement, it is more likely to be attributable to optimization of indication, development in surgical techniques, and increased use of perioperative chemotherapy.

No MeSH data available.


Related in: MedlinePlus